Trials / Recruiting
RecruitingNCT07213674
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xaluritamig | Xaluritamig will be administered IV. |
| DRUG | Abiraterone acetate | Abiraterone acetate will be administered orally. |
| DRUG | Docetaxel | Docetaxel will be administered IV. |
| DRUG | Cabazitaxel | Cabazitaxel will be administered IV. |
Timeline
- Start date
- 2025-11-28
- Primary completion
- 2030-01-07
- Completion
- 2032-08-30
- First posted
- 2025-10-09
- Last updated
- 2026-04-16
Locations
122 sites across 18 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Greece, Italy, Japan, Netherlands, Portugal, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07213674. Inclusion in this directory is not an endorsement.